A selective, ATP-competitive inhibitor Pim-1 (IC₅₀ = 21 nM) and Pim-2 (IC₅₀ = 100 nM) protein kinases. Blocks mTORC1 activity via activation of AMPK. SMI-4a has been found to inhibit prostate cancer cell growth and induce G1 phase cell-cycle arrest in precursor T-cell lymphoblastic leukemia/lymphoma cell lines.